About University Dermatology Group
Clinical Trials at University Dermatology Group
During the past decade, University Dermatology Group conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on
average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at University Dermatology Group
According to Clinical.Site data, the most researched conditions in "University Dermatology Group" are
"Psoriasis" (2 trials). Many other conditions were trialed in "University Dermatology Group" in a lesser frequency.
Clinical Trials Intervention Types at University Dermatology Group
Most popular intervention types in "University Dermatology Group" are "Drug" (2 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "BMS-986165" (2 trials), "Apremilast" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.
Clinical Trials Genders at University Dermatology Group
The vast majority of trials in "University Dermatology Group" are
2 trials for "All" genders.
Clinical Trials Status at University Dermatology Group
Currently, there are NaN active trials in "University Dermatology Group".
undefined are not yet recruiting,
undefined are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 1 completed trials in University Dermatology Group,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in University Dermatology Group, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".